← Back to Search

Algorithm-based Screening

Diabetes Screening for Early Detection of Pancreatic Cancer (EDI Trial)

N/A

Waitlist Available

Led By Avinash Kambadakone-Ramesh, MD, FRCR

Research Sponsored by Pancreatic Cancer Action Network

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patient must have hyperglycemia and/or diabetes as defined by specific glycemic parameters

Patient must be ≥50 and ≤85 years of age at the time of diagnosis (index date Parameters of Diabetes Mellitus (PDM))

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline and approximately every six months for up to five years

Awards & highlights

EDI Trial Summary

This trial is testing whether screening people with new onset diabetes can help detect pancreatic cancer earlier.

Who is the study for?

This trial is for people aged 50-85 who've recently developed high blood sugar or diabetes, as shown in their medical records. They must consent to the study and not be on any cancer treatments, have no history of hyperglycemia/diabetes or pancreatic cancer diagnosis before the study start date, and not be taking steroids.Check my eligibility

What is being tested?

The trial tests if a special score (ENDPAC) combined with abdominal imaging can find pancreatic cancer early in those newly diagnosed with high blood sugar or diabetes. It's a randomized controlled trial across multiple centers.See study design

What are the potential side effects?

Since this trial involves diagnostic procedures rather than medications, typical drug side effects are not expected. However, there may be minimal risks associated with undergoing abdominal imaging.

EDI Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have high blood sugar or diabetes.

Select...

I am between 50 and 85 years old and was diagnosed with diabetes.

EDI Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline and approximately every six months for up to five years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline and approximately every six months for up to five years

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and approximately every six months for up to five years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Earlier detection of pancreatic ductal adenocarcinoma (PDAC)

Secondary outcome measures

Contribute to NOD biobank

Depression and Anxiety as early indicators

Determine the proportion of incidental findings

+6 more

EDI Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Intervention ArmExperimental Treatment2 Interventions

Two interventions are performed: Have Enriching New-onset Diabetes for Pancreatic Cancer (ENDPAC) score calculated, and if Score is >0, Have abdominal imaging performed.

Group II: Observation ArmActive Control1 Intervention

Passive follow-up by electronic medical record for study endpoints of pancreatic cancer diagnosis.

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Pancreatic Cancer Action NetworkLead Sponsor

5 Previous Clinical Trials

961 Total Patients Enrolled

Fred Hutchinson Cancer CenterOTHER

556 Previous Clinical Trials

1,330,768 Total Patients Enrolled

National Institutes of Health (NIH)NIH

2,696 Previous Clinical Trials

6,940,079 Total Patients Enrolled

Media Library

Enriching New-onset Diabetes for Pancreatic Cancer (ENDPAC) score (Algorithm-based Screening) Clinical Trial Eligibility Overview. Trial Name: NCT04662879 — N/A

Pancreatic Cancer Research Study Groups: Intervention Arm, Observation Arm

Pancreatic Cancer Clinical Trial 2023: Enriching New-onset Diabetes for Pancreatic Cancer (ENDPAC) score Highlights & Side Effects. Trial Name: NCT04662879 — N/A

Enriching New-onset Diabetes for Pancreatic Cancer (ENDPAC) score (Algorithm-based Screening) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04662879 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any opportunities to participate in this experimental research?

"According to clinicaltrials.gov, this ongoing medical trial is accepting participants since it was first made available on October 14th 2021 and last updated on March 29th 2022."

Answered by AI

What is the total number of participants taking part in this research program?

"Affirmative. Clinicaltrials.gov indicates that this medical trial is presently recruiting and opened for application on October 14th 2021. The study requires 12500 participants in total, to be gathered from 3 distinct centres of care."

Answered by AI

Is it possible for me to join this research program?

"Candidates for this clinical trial must have diabetes mellitus and be between the ages of 50 to 85. The study is enrolling up to 12500 participants."

Answered by AI

Is the age restriction for this research study limited to those over 25 years old?

"This clinical trial requires that participants be between 50 and 85 years of age. For those under 18, there are 194 trials available, while 1681 options exist for individuals above the retirement age."

Answered by AI